( al cancer) high grade cervicaldysplas...)Gardasil Demonstrates Up to 100% Efficacy,Health

al cancer), high grade cervical dysplasia CIN2/3 (precancerous cervical lesions), high grade vulvar dysplastic lesions VIN 2/3 (precancerous vulvar lesions) and external genital warts (condyloma acuminata) caused by Human Papillomavirus types 6, 11, 16 and 18.

Worldwide availability of Gardasil®
Gardasil® has been developed by Merck & Co., Inc. and Sanofi Pasteur MSD. In Europe, the vaccine is marketed by Sanofi Pasteur MSD.
Gardasil® has been approved in 70 countries (many under accelerated review timelines), including the EU, the US, Canada and Australia and has met with very broad acceptance. Additional applications are currently under review with regulatory agencies in many more countries around the world.
The EU licensed Gardasil® within just 9 months compared to a usual review time of 13-15 months. After gaining the license in September 2006 Sanofi Pasteur MSD has made Gardasil® available in 18 European countries.
Merck is actively working to accelerate the availability of Gardasil® in the developing world. Clinical trials for the development of Gardasil® have already included participants from 33 countries on 5 continents in a variety of settings. Clinical studies in developing world countries are being initiated to assess the efficacy of Gardasil® in other environments. Merck will donate free vaccine to the non-profit organisation PATH to support demonstration studies to accelerate the availability of Human Papillomavirus vaccines in the most impoverished countries. Merck is also working with India's Council of Medical Research to study Gardasil® in India. Merck will make our new vaccines, including Gardasil®, available to developing world countries at dramatically lower prices.

About Sanofi Pasteur MSD
Sanofi Pasteur MSD is a joint venture between sanofi pasteur, the vaccine division of sanofi-aventis, and Merck & Co., Inc. Combining innovation and expertise, Sanofi
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer